Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON--(BUSINESS WIRE)-- Genialis, the RNA biomarker company, ...
The MarketWatch News Department was not involved in the creation of this content. The demand for digital biomarkers is rapidly increasing, largely due to the worldwide rise in chronic illnesses such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback